- Membrane Proteins
- Accession Number
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Drug Drug Description Etanercept A protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis. Gramicidin D A bactericidal antibiotic used in the treatment of dermatological and ophthalmic infections. Enfuvirtide An HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals. Colistin A polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria. Adecatumumab Investigated for use/treatment in breast cancer and prostate cancer. Tifuvirtide Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection. Tisagenlecleucel A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma. TG4010 Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer. Tecemotide Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung. Isoxaflutole Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder. Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Colistimethate An antibiotic indicated for treatment of infections caused by susceptible strains of certain gram-negative bacilli. It is particularly useful for targeting sensitive strains of Pseudomonas aeruginosa. Dirucotide For the treatment of multiple sclerosis (MS). Topsalysin Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Thrombomodulin Alfa Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. Pegdinetanib Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration. Nelipepimut-S Investigated for use/treatment in prostate cancer and breast cancer. Onercept Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease. AMGN-0007 Investigated for use/treatment in osteoporosis and bone metastases. Omiganan Investigated for use/treatment in bacterial infection and rosacea. Pegsunercept Investigated for use/treatment in rheumatoid arthritis. Bordetella pertussis pertactin antigen Bordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis . Luspatercept An erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms. Tiplimotide Tiplimotide has been used in trials studying the treatment of Multiple Sclerosis. Dalantercept Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma). Recombinant CD40-ligand Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma). Ipafricept Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors). Fibronectin Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix). Asunercept Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme). Cystic fibrosis transmembrane conductance regulator Cystic fibrosis transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis). ALT-801 ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia). Brexucabtagene autoleucel A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. Iseganan Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer). VEGFR2-169 VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)). Pexiganan Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers). Pam2csk4 Not Available Vasomera Not Available Idecabtagene vicleucel An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. Reltecimod Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections). Myelin basic protein Not Annotated GI-6207 Not Annotated Batoclimab Batoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP). Eftilagimod alfa Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma). CDX-1135 CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and... P-113D For the potential treatment of cystic fibrosis and bacterial infections. GP-100 antigen GP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma). EDI-200 EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1. CHF5633 CHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a synthetic SP-B analogue. Lixisenatide A GLP-1 receptor agonist used for the management of type 2 diabetes mellitus. Tirzepatide A dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise.
- Drugs & Drug Targets